Pregnancy & Lactation : הריון/הנקה

4.6   Fertility, Pregnancy and lactation
For Articaine HCl 4% and Epinephrine 1:200,000 no clinical data on exposed pregnancies are available. In regard of articaine animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). Animal studies carried out with epinephrine have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.
Caution should be exercised when prescribing to pregnant women.
It is unknown whether articaine and epinephrine is excreted in human breast milk. The excretion of articaine and epinephrine in milk has not been studied in animals. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Articaine HCl 4% and Epinephrine 1:200,000 should be made taking in to account the benefit of breastfeeding to the child and the benefit of Articaine HCl 4% and Epinephrine 1:200,000 therapy to the women. Therefore, nursing mothers should milk and discard the first mother’s milk following anaesthesia with articaine.